Good
Mostly Aligned
Patient Risk:
Low
Summary
Dosing statements are supported by the label; one claim about brand-name exclusivity is not supported by the label.
Category Scores
Accurate Statements
The label indicates ZONTIVITY tablets contain 2.08 mg of vorapaxar and instructs to take one 2.08 mg tablet daily.
11 DESCRIPTION; 2 DOSAGE AND ADMINISTRATION
Unsupported Statements
In the US, Zontivity is brand-name only.
Not explicitly stated in the label; the label uses the brand name but does not claim exclusivity or lack of generics.
Contradictions
Important Omissions
The dosing claim omits safety-critical information such as boxed warnings for major bleeding and contraindications (e.g., history of stroke/TIA, intracranial hemorrhage), and use in pregnancy/pediatrics.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Claims focus on dosing; no new safety risk introduced; but omissions could miss safety warnings.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Brand-name exclusivity statement is unsupported
Suggested Improvement
If evaluating label claims, restrict to dosing as shown; avoid implying brand exclusivity; consider noting that label uses brand name but does not assert exclusivity.